EDP-323

Small molecule

Partialsignal

Evidence outlook · lead readout

NCT06170242 · Respiratory Syncytial Virus Infection

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

NCT06170242: In this randomized, double-blind, placebo-controlled Phase 2a challenge study, healthy volunteers were deliberately infected with RSV and then treated with EDP-323 or placebo. Both EDP-323 doses significantly reduced the amount of virus detected in nasal samples compared with placebo, but the trial measured viral load rather than a direct clinical symptom or disease outcome.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Respiratory Syncytial Virus Infection
Phase 1 (3)
Other / comorbidity
NCT06917508 · Enanta Pharmaceuticals, Inc
2025-03-13 – 2025-06-13 · RSV Infection, Drug Drug Interaction
What this study did
NCT05587478 · Enanta Pharmaceuticals, Inc
2022-09-29 – 2023-03-29 · RSV Infection
What this study did

Competitive landscape

This drug's own stage for Respiratory Syncytial Virus Infection: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
EDP-323: this drugPhase 2Small moleculeRSV L proteinPartial signal
NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743)
Clesrovimab (Enflonsia)ApprovedMonoclonal antibodyRSV F proteinnot yet gradedNo reviewed efficacy summary in this indication
mRESVIAApprovedVaccineRSV pre-F proteinPartial signal
NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses).
ZelicapavirPhase 2Small moleculeRSV N protein (nucleoprotein)Weak signal
NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed
NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants
GSK5893818
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0256
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0291
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0340
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0341
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.